Drug intelligence / Profile preview

isophosphoramide mustard

Development stage
Unknown
Lead developer
Southern Research
Modality
Small Molecules
Administration
Intravenous, Oral
01

Overview

Isophosphoramide mustard is a small-molecule bifunctional alkylating agent and the principal cytotoxic metabolite of ifosfamide; it forms DNA interstrand cross-links (notably via N7-guanine) yielding irreparable 7-atom cross-links that inhibit DNA replication and transcription, leading to tumor cell death. Preclinical studies showed antitumor activity comparable to cyclophosphamide and ifosfamide across multiple murine tumor models, including activity in cyclophosphamide-resistant leukemia, though with lower activity in intracerebral P388 and B16 melanoma models. As the active moiety of ifosfamide, development efforts included stabilized salt forms such as a lysine salt (ZIO-201) to improve solution stability and enable IV and oral administration, with early clinical development in advanced cancers and sarcoma. Unlike ifosfamide, IPM itself is not metabolized to acrolein or chloroacetaldehyde, suggesting a lower risk of bladder and CNS toxicity when delivered directly as stabilized formulations.

Other names
isophosphoramide mustard lysineIPM-lysinepalifosfamide
02

Targets

DNA

Beyond the preview

Go deeper on isophosphoramide mustard.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on isophosphoramide mustard.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call